Up Next
-
7m 30sPart 2 | Session 4 1.3: General management of the nephrotic syndrome
-
31m 57sPart 2 | Session 5 Panel Discussion
-
1m 4sPart 3 | Session 1 Welcome and Introduction
-
8m 2sPart 3 | Session 2 Management of iron deficiency in heart failure: new evidence, new guidelines
-
10m 31sPart 3 | Session 3 Iron deficiency in chronic kidney disease: why iron matters beyond anaemia
-
11m 28sPart 3 | Session 4 Interactive panel discussion
-
1m 29sPart 4 | Session 1 Introduction
-
16m 37sPart 4 | Session 2 2.1: The new ESC HF guidelines
-
8m 23sPart 4 | Session 3 2.2: Personalised management
-
9m 7sPart 4 | Session 4 2.3: Preventive cardiology
-
25m 36sPart 4 | Session 5 Panel Discussion
-
1m 9sPart 6 | Session 1 Introduction
-
8m 4sPart 6 | Session 2 3.1: Focus on diabetology
-
9m 10sPart 6 | Session 3 3.2: Focus on cardiology
-
7m 30sPart 6 | Session 4 3.3: Focus on nephrology
-
33m 58sPart 6 | Session 5 Panel Discussion
-
1m 13sPart 7 | Session 1 Introduction
-
7m 28sPart 7 | Session 2 The meaning of Hemoglobin A1C for the nephrologist
-
8m 10sPart 7 | Session 3 The meaning of Hemoglobin A1C for the cardiologist
-
14m 13sPart 7 | Session 4 Panel discussion
-
2m 6sPart 8 | Session 1 Introduction
-
8m 15sPart 8 | Session 2 4.1: GLP-1RA and CVD in diabetes
-
8m 15sPart 8 | Session 3 4.2: GLP-1 RA and kidney disease in diabetes
-
6m 6sPart 8 | Session 4 4.3: Obesity and cardio-metabolic disease: Role of GLP-1RA
-
1m 6sPart 9 | Session 1 Welcome and introduction
-
5m 20sPart 9 | Session 2 Cardio-renal-metabolic disease in a nutshell
-
6m 45sPart 9 | Session 3 SGLT2 inhibitors in patients with type 2 diabetes and comorbidities
-
6m 42sPart 9 | Session 4 SGLT2 inhibitors in patients with heart failure and comorbidities
-
5m 2sPart 9 | Session 5 SGLT2 inhibitors in patients with chronic kidney disease and comorbidities
-
13m 56sPart 9 | Session 6 Panel discussion
-
1m 39sPart 10 | Session 1 Introduction
-
8m 59sPart 10 | Session 2 5.1: Diagnosis, pathophysiology, epidemiology
-
10mPart 10 | Session 3 5.2: Diabetes
-
8m 6sPart 10 | Session 4 5.3: In chronic kidney disease
-
7m 3s
-
25m 14sPart 10 | Session 6 Panel discussion
-
1mPart 11 | Session 1 Introduction
-
7m 24sPart 11 | Session 2 Mechanism of disease interplay between CVD and CKD
-
9m 6sPart 11 | Session 3 The use of SGLT2is in patients with CKD and CVD with and without diabetes
-
13m 6sPart 11 | Session 4 Panel discussion
-
1m 15sPart 13 | Session 1 Introduction
-
8m 21sPart 13 | Session 2 6.1: EMPEROR-Preserved
-
8m 55sPart 13 | Session 3 6.2: Preserved HF
-
7m 33sPart 13 | Session 4 6.3: Dronedarone in AF management: A 2022 update
-
10m 41sPart 13 | Session 5 6.4: Upcoming trials in 2022 (Deliver, Diamond, Iron Man)
-
24m 16sPart 13 | Session 6 Panel discussion
-
52sPart 15 | Session 1 Introduction
-
5m 46sPart 15 | Session 2 The case for early identification, risk stratification and treatment of CKD
-
5m 24sPart 15 | Session 3 Protecting the kidney and the heart: the cardiologist's perspective
-
6m 52sPart 15 | Session 4 Identifying high-risk patients: the primary care physician's perspective
-
11m 16sPart 15 | Session 5 Panel discussion
-
57sPart 16 | Session 1 Welcome and introduction
-
8m 59sPart 16 | Session 2 8.1: Cachexia in CV disease
-
8m 30sPart 16 | Session 3 8.2: Cachexia in CKD
-
8m 37sPart 16 | Session 4 8.3: Muscle wasting in stroke
-
31m 48sPart 16 | Session 5 Panel discussion
-
28m 46s
-
1m 44sPart 18 | Session 1 Introduction
-
7m 46sPart 18 | Session 2 9.1: Diabetes and CVD today
-
3m 53sPart 18 | Session 3 9.2: Diabetes and kidney today
-
7m 30sPart 18 | Session 4 9.3: The cross-talk between kidney and heart
-
7m 23sPart 18 | Session 5 9.4: Therapeutic solution
-
24m 37sPart 18 | Session 6 Panel discussion
-
30m 11sPart 19 | Session 1 SGLT2 inhibition in the comorbid CKD patient
-
4m 26sPart 19 | Session 2 Panel discussion
-
2m 10sPart 20 | Session 1 Introduction
-
8m 29sPart 20 | Session 2 10.1: Screening of kidney disease
-
8m 11sPart 20 | Session 3 10.2: Screening of heart failure
-
8m 15sPart 20 | Session 4 10.3: Horizons opened by the screening
-
33m 48sPart 20 | Session 5 Panel discussion
-
1m 14sPart 21 | Session 1 Welcome and introduction
-
9m 27sPart 21 | Session 2 New developments in SGLT2 inhibitor use in HFrEF and HFpEF
-
9m 15sPart 21 | Session 3 Implementing guidelines in clinical practice
-
10m 43sPart 21 | Session 4 Panel discussion
-
2m 7sPart 22 | Session 1 Introduction
-
8m 22sPart 22 | Session 2 In ambulatory HFrEF and HFpEF
-
8m 22sPart 22 | Session 3 When to start after acute decompensation
-
9m 38sPart 22 | Session 4 Improving QoL and symptoms
-
2m 24sPart 22 | Session 5 The case of acute MI
-
24m 22sPart 22 | Session 6 Panel discussion
-
50sPart 24 | Session 1 Introduction
-
8m 22sPart 24 | Session 2 Practical issues of managing weight loss in CRM disease: the therapeutic options
-
8m 9sPart 24 | Session 3 Managing weight loss in CRM disease: the nephrologist's perspective
-
8m 31sPart 24 | Session 4 Managing weight loss in CRM disease: the diabetologist's perspective
-
8m 33sPart 24 | Session 5 Managing weight loss in CRM disease: the cardiologists' perspective
-
25m 47sPart 24 | Session 6 Panel discussion
-
1m 30sPart 25 | Session 1 Welcome and introduction
-
16m 1sPart 25 | Session 3 Interactive panel discussion
-
31m 2s
-
2m 39sPart 27 | Session 1 Introduction
-
6m 32sPart 27 | Session 2 DAPA CKD: Key lessons from subgroup analyses
-
6m 41sPart 27 | Session 3 FIDELIO/FIGARO DKD
-
8m 34sPart 27 | Session 4 FIDELITY - Main lessons including subgroup analyses
-
11m 1sPart 27 | Session 5 Chlortalidone in CKD stage 4: A new look at an old drug
-
25m 1sPart 27 | Session 6 Panel discussion
-
2m 1sPart 28 | Session 1 Introduction
-
4m 33sPart 28 | Session 2 Screening and diagnosis best practices
-
5m 48sPart 28 | Session 3 Primary care perspective and challenges
-
10m 3sPart 28 | Session 4 Reducing CV risks and new treatment options: case discussion
-
17m 19sPart 28 | Session 5 Panel discussion
-
1m 23sPart 29 | Session 1 Introduction
-
8m 38sPart 29 | Session 2 Digital technologies in CV disease
-
7m 39sPart 29 | Session 3 Remote monitoring of HF
-
34m 11sPart 29 | Session 4 Panel discussion
-
5m 21sPart 30 | Session 1 Introduction
-
8m 24sPart 30 | Session 2 Ascend D and ASCEND ND
-
7m 42sPart 30 | Session 3 The moving field of drug nephrotoxicity
-
8m 22sPart 30 | Session 4 The role of new potassium binding agents in cardio-renal medicine
-
31m 33sPart 30 | Session 5 Panel discussion
-
32m 21s
-
1m 50sPart 32 | Session 1 Introduction
-
6m 50sPart 32 | Session 2 Cardio-centric approach
-
9m 15sPart 32 | Session 3 Gluco-centric approach
-
15m 19sPart 32 | Session 4 Combination therapy as starting option
-
27m 15sPart 32 | Session 5 Panel discussion
-
31m 10s
-
55sPart 2 | Session 1 Welcome and introduction
-
9m 28sPart 2 | Session 2 1.1: BP in CKD Guidelines
Overview
e-SPACE CARDIO-RENAL-METABOLIC 2022, held on 4-6 March 2022, was the second edition of the global online conference on cardio renal metabolic diseases.
The organisers, under the direction of a world-renowned scientific committee, brought together leading experts in cardiology, nephrology, and diabetology to share clinical practice strategies in treating the inter-related diseases now affecting hundreds of millions people worldwide.
This on-demand version of the event comprises:
- Presentations and discussions with leading experts
- Evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity
- Insight to SLGT2i, GLP-1RA and other emerging therapies
- 'Meet the Expert' sessions
e-SPACE Cardio-Renal-Metabolic 2022 was supported by the following companies:
More from this programme
Part 1
Meet the Expert: IgA nephropathy: current optimal management
Part 2
Session 1: The new KDIGO guidelines
Part 3
Industry Session: Iron deficiency in heart failure and kidney disease: interdisciplinary crosstalk
Part 4
Session 2: Recent CV guidelines and treatment algorithms
Part 5
Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes
Part 6
Session 3: Management of SGLT2 a practical approach
Part 7
Meet the Experts: The meaning of Hemoglobin A1C for the nephrologist and the cardiologist
Part 8
Session 4: GLP-1RA and cardio-metabolic disease in diabetes
Part 9
Industry Session: SGLT2 inhibitors in cardio-renal-metabolic disease: optimizing the patient's journey
Part 10
Session 5: HFpEF: tackling a multidisciplinary problem
Part 11
Meet the Experts: CKD progression in CVD screening and follow-up
Part 12
Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM
Part 13
Session 6: New trial update in cardiology
Part 14
Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group
Part 15
Meet the Expert: Multidisciplinary management of cardio-renal-metabolic disease: focus on the kidney
Part 16
Session 8: Sarcopenia, frailty malnutrition and cachexia
Part 17
Meet the Expert: HIF PHI: What do we know and don't know in 2022
Part 18
Session 9: The cardio-kidney interaction: relevance to diabetes
Part 19
Industry Session: SGLT2 inhibition in the comorbid CKD patient
Part 20
Session 10: Why and how to screen for heart failure and kidney disease in diabetes
Part 21
Meet the Expert: SGLT2 inhibitors in heart failure: Improving outcomes across the spectrum of the disease
Part 22
Session 11: SGLT2 inhibition in clinical practice
Part 23
Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist
Part 24
Session 12: Managing obesity in the CRM setting
Part 25
Meet the Experts: Personalized care of patients with heart failure: hyperkalemia as a barrier to optimal medical therapy
Part 26
Meet the Expert: SGLT2, the statin of the 21st century
Part 27
Session 13: New trial update in nephrology
Part 28
Meet the Experts: Reducing the risk of cardiovascular events for patients with CKD and T2DM: new treatment options
Part 29
Session 14: Telemedicine in CRM
Part 30
Session 15: New drugs, new hopes and sometimes risks
Part 31
Meet the Expert: Management of worsening HF
Part 32